Through significant advancements in biomedical innovation, new promising gene and cell therapy treatments may be the key to unlocking the cure to debilitating genetic, oncologic, and other diseases that were once deemed incurable. The first cell therapy treatment was approved in the US in 2017. Currently, four products are approved in the US, with six products approved in Europe. Moving forward, the US Food and Drug Administration (FDA) expects those numbers to grow exponentially.
Because currently approved gene and cell therapy treatments target rare diseases, the FDA does not require a large patient population, as it does for traditional drug approvals. This means a shorter time to market and earlier access for patients; but, it also means more uncertainties about the benefits of the treatment versus adverse effects. As a result, in some instances, the FDA requires a post-approval data collection for up to 15 years. Following patients for extended periods of time and collecting data on patient outcomes can help resolve many of the uncertainties presented by cell and gene therapies, but the mechanisms for data collection and the types of data collected can vary based on different stakeholders’ perspectives.
This report explores the data needs of different stakeholder groups, the strengths and limitations of current models for data collection, and future considerations relevant to each stakeholder group. Multi-stakeholder collaborations and partnerships are crucial and should strive to center patient preferences and unmet needs.
Frontotemporal dementia (FTD) refers to a family of neurodegenerative conditions that cause changes in behavior, mood, executive function, language, memory, and motor function. As many as 30,000 people are living with FTD in the United...
The Milken Institute Center for Strategic Philanthropy and the Ann Theodore Foundation have released a new request for proposals (RFP) focused on understanding the underlying biology of sarcoidosis. Applications are open through January 20...
Countries undergoing population aging today are facing a much different experience than their historical counterparts. One only needs to look at the countries in Asia to see how these trends are unfolding. Demographic aging is happening...
Even before the onset of the COVID-19 pandemic, the United States was confronted with a number of significant policy concerns. Today, working together to solve those challenges is more imperative than ever. The Milken Institute is committed...
The 26th annual Milken Institute Global Conference convened the best minds in the world to tackle its most urgent challenges and realize its most exciting opportunities. Throughout the four-day event, our health teams curated nearly three...
Technical Update Dementia presents a pernicious gender-based health disparity in the United States, inflicting a disproportionate burden on women as both patients and caregivers. Given the rapid increase in the population of older Americans...
Nationwide protests in the summer of 2020 sparked many of the largest US corporations to pledge more than $200 billion to advance racial equity and confront the nation’s history of systemic racism. Nonprofits, government agencies, and...
The Ann Theodore Foundation Breakthrough Sarcoidosis Initiative (ATF-BSI) is now accepting applications for two-year research projects that seek to increase our foundational understanding of sarcoidosis through projects focused on the...
The Financial Innovations Labs® and FasterCures teams have collaborated on a project to identify new models for financing the antimicrobial resistant antibiotic pipeline. These past 18 months have demonstrated how consequential public...